Cargando…

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib

OBJECTIVE: Alectinib has a much better central nervous system transmission than crizotinib in patients diagnosed with anaplastic lymphoma kinase mutation-positive nonsmall cell lung carcinoma. We aimed to investigate alectinib’s efficacy in the treatment and its place in the first-line treatment and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katgı, Nuran, Çimen, Pınar, Akyol, Murat, Gürsoy, Pınar, Agüloğlu, Nurşin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Turkish Thoracic Society 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544624/ https://www.ncbi.nlm.nih.gov/pubmed/37485706 http://dx.doi.org/10.5152/ThoracResPract.2023.22200

Ejemplares similares

The Prognostic Value of (18)F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma
por: Agüloğlu, Nurşin, et al.
Publicado: (2022)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status
por: Kanai, Osamu, et al.
Publicado: (2017)

Successful alectinib treatment after crizotinib‐induced interstitial lung disease
por: Fujiuchi, Satoru, et al.
Publicado: (2016)

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)

Successful treatment with crizotinib after alectinib-induced interstitial lung disease
por: Zhu, Ning, et al.
Publicado: (2021)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion
por: Pan, Yingying, et al.
Publicado: (2021)

Observation of Alectinib‐ and Crizotinib‐ included chemotherapy in children with ALK‐positive anaplastic large cell lymphoma: A single institutional experience
por: He, Yingyi, et al.
Publicado: (2022)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
por: Kitadai, Rui, et al.
Publicado: (2018)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
por: Liu, Maobai, et al.
Publicado: (2019)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Control of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
por: Kwok, Wang Chun, et al.
Publicado: (2017)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
por: Sivignon, Marine, et al.
Publicado: (2020)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Case Report: Treatment of Alectinib in NSCLC With Brain Metastasis Patient Refractory to Radiotherapy After Resistance to Crizotinib
por: Zhang, Chunzhi
Publicado: (2021)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
por: Testa, Stefano, et al.
Publicado: (2021)

PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment
por: Gürsoy, Pınar, et al.
Publicado: (2022)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
por: Huang, Xing
Publicado: (2018)

Influence of alectinib and crizotinib on ionizing radiation - in vitro analysis of ALK/ROS1-wildtype lung tissue cells
por: Jost, Tina, et al.
Publicado: (2022)

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
por: Novello, S, et al.
Publicado: (2018)

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA
por: DiBonaventura, Marco D, et al.
Publicado: (2017)

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
por: Gadgeel, S, et al.
Publicado: (2018)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2021)

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
por: Hayashi, Nobuyoshi, et al.
Publicado: (2017)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
por: Okuma, Yusuke, et al.
Publicado: (2015)

Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial
por: Fukano, Reiji, et al.
Publicado: (2020)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma
por: Verran, Julian, et al.
Publicado: (2022)

Metabolites of alectinib in human: their identification and pharmacological activity
por: Sato-Nakai, Mika, et al.
Publicado: (2017)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
por: Noguchi, Kazuhiro, et al.
Publicado: (2023)

Marked improvement in leptomeningeal carcinomatosis and spinal cord metastases following alectinib treatment of crizotinib-resistant, ALK-positive lung adenocarcinoma
por: Kuribayashi, Hidehiko, et al.
Publicado: (2015)

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
por: Tang, Hao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kdeo95t4uf5k6sabbqbt3i60li